Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Advertise with Us Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Medical Developments International Limited (AU:MVP)

ASX:MVP

MVP

Medical Developments International Limited

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding AU:MVP?

Track your performance easily

Link Broker

Medical Developments International Limited (MVP) Share Price & Analysis

7 Followers

MVP Stock Chart & Stats

Advanced Chart >

Day’s RangeAU$0 - AU$0

52-Week RangeAU$0.36 - AU$1.05

Previous CloseAU$0.42

Volume41.27K

Average Volume (3M)185.52K

Market Cap

AU$46.75M

Enterprise ValueAU$29.17M

Total Cash (Recent Filing)AU$20.40M

Total Debt (Recent Filing)AU$2.81M

Price to Earnings (P/E)―

Beta0.37

Next Earnings

Feb 20, 2025

EPS Estimate

-AU$0.02

Last Dividend Ex-Date

Mar 05, 2020

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares OutstandingN/A

10 Day Avg. Volume115,199

30 Day Avg. Volume185,520

Standard Deviation0.20

R-Squared0.26

Alpha-0.03

Financial Highlights & Ratios

Price to Book (P/B)0.00

Price to Sales (P/S)3.06

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Medical Developments International Limited News

PremiumCompany Announcements

Medical Developments International Shares Business Outlook

7d ago

PremiumCompany Announcements

Jencay Capital Acquires Stake in Medical Developments

1M ago

PremiumCompany Announcements

Medical Developments International Reports Strong AGM Outcomes

1M ago

PremiumCompany Announcements

Medical Developments International Highlights Market Strategy

1M ago

PremiumCompany Announcements

Medical Developments International Sees Growth Amid Challenges

1M ago

PremiumCompany Announcements

Medical Developments International Reports Revenue Growth and Strategic Expansion

1M ago

PremiumCompany Announcements

Medical Developments Intl Ends 529K Securities

2M ago

PremiumCompany Announcements

Medical Developments’ Hybrid AGM Scheduled for October

2M ago

See More AU:MVP News >

Financials

Annual

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

1.32% Insiders

― Mutual Funds

― Other Institutional Investors

98.68% Public Companies and

Individual Investors

Detailed Ownership Overview >

MVP FAQ

What was Medical Developments International Limited’s price range in the past 12 months?

Medical Developments International Limited lowest share price was AU$0.36 and its highest was AU$1.05 in the past 12 months.

What is Medical Developments International Limited’s market cap?

Currently, no data Available

When is Medical Developments International Limited’s upcoming earnings report date?

Medical Developments International Limited’s upcoming earnings report date is Feb 20, 2025 which is in 85 days.

How were Medical Developments International Limited’s earnings last quarter?

Medical Developments International Limited released its earnings results on Aug 25, 2024. The company reported -AU$0.348 earnings per share for the quarter, missing the consensus estimate of -AU$0.203 by -AU$0.145.

Is Medical Developments International Limited overvalued?

According to Wall Street analysts Medical Developments International Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medical Developments International Limited pay dividends?

Medical Developments International Limited pays a Annually dividend of AU$0.02 which represents an annual dividend yield of N/A. See more information on Medical Developments International Limited dividends here

What is Medical Developments International Limited’s EPS estimate?

Medical Developments International Limited’s EPS estimate is -AU$0.02.

How many shares outstanding does Medical Developments International Limited have?

Medical Developments International Limited has 112,658,325 shares outstanding.

What happened to Medical Developments International Limited’s price movement after its last earnings report?

Medical Developments International Limited reported an EPS of -AU$0.348 in its last earnings report, missing expectations of -AU$0.203. Following the earnings report the stock price went up 2.353%.

Which hedge fund is a major shareholder of Medical Developments International Limited?

Currently, no hedge funds are holding shares in AU:MVP

---

Medical Developments International Limited Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-64.53%

Trailing 12-Months

Asset Growth

-41.75%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medical Developments International Limited

Medical Developments International Ltd is a specialized healthcare company. It manufactures and distributes the pharmaceutical drug and medical and veterinary equipment. The company provides a range of products in the areas of pain management, asthma, and resuscitation, plus veterinary equipment. It is organized into three business units: Pharmaceuticals, Medical Devices, and Veterinary products. Majority of its revenue comes from Pharmaceuticals Unit which engages in the sale of Penthrox within Australia, New Zealand, Europe the UK and some sales in Canada, the Middle East, Asia and South Africa.

---

MVP Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"AU$2","-1":"-AU$1","-0.25":"-AU$0.25","0.5":"AU$0.5","1.25":"AU$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jun<br/>2023","9":"Sep<br/>2023","12":"Nov<br/>2023","25":"Nov<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.7107692307692308,0.6515384615384615,0.5923076923076923,0.5330769230769231,0.47384615384615386,0.4146153846153846,0.3553846153846154,0.29615384615384616,0.2369230769230769,0.1776923076923077,0.11846153846153851,0.0592307692307692,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.7107692307692308,0.6515384615384615,0.5923076923076923,0.5330769230769231,0.47384615384615386,0.4146153846153846,0.3553846153846154,0.29615384615384616,0.2369230769230769,0.1776923076923077,0.11846153846153851,0.0592307692307692,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.7107692307692308,0.6515384615384615,0.5923076923076923,0.5330769230769231,0.47384615384615386,0.4146153846153846,0.3553846153846154,0.29615384615384616,0.2369230769230769,0.1776923076923077,0.11846153846153851,0.0592307692307692,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.56,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.44,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.45,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.37,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.08,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.97,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.8,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.75,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.02,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.84,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.83,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.78,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.77,"date":1700784000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >